================================================================================
U.S. SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): October 10, 2008
ONCOLOGIX TECH, INC.
---------------------------------------------------------
(Name of Small Business Issuer as Specified in Its Charter)
0-15482
----------------------
(Commission File Number)
Nevada 86-1006416
------------------------------ -----------------
(State or other jurisdiction of (I.R.S. Employer
incorporation or organization) Identification No.)
P.O. Box 8832
Grand Rapids, MI 49518-8832
--------------------------------------
(Address of principal executive offices)
(616) 977-9933
-------------------------
(Issuer's telephone number)
Check the appropriate box below if the Form 8-K is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions:
[ ] Written communications pursuant to Rule 425 under the Securities Act (17
CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17
CFR 240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.13e-4(c))
================================================================================
Item 1.01 Entry into a Material Definitive Agreement.
On October 10, 2008 the Registrant entered into an agreement with the
University of Maryland pursuant to which the Master License Agreement between
the parties was modified so as to extend until January 5, 2009 the
accomplishment of the "milestone" consisting of the filing of an Investigational
Device Exemption for a Licensed Product to the FDA or any foreign equivalent of
the Company commences a Clinical Trial of a Licensed Product. The previous due
date for these milestone was September 16, 2008. The extension is subject to
each of the following conditions: (1) that on before November 30, 2008 the
University shall have received from IUT (the proposed purchaser of our
Oncosphere assets) a Research and Development and Business Plan, reasonably
acceptable to the University, for the commercialization of the Oncosphere
technology; (2) that on or before January 5, 2009, the proposed Asset Sale to
IUT shall have been approved by the shareholders of the Registrant and the sale
has been consummated; (3) that IUT (or its subsidiary) and the University shall
have entered into a new mutually acceptable Master License Agreement with
respect to the Oncosphere technology; (4) the Registrant shall have amended its
Articles Of Incorporation to increase its authorized capital stock as proposed
in a certain Proxy Statement that has been filed with the Securities and
Exchange Commission but not yet become effective ; and (5) that 2,000,000 shares
of the Registrant's common stock shall be issued and sold to the University in
consideration of the extension agreement.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
Exhibit Title
99 License Modification Agreement
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant caused this report to be signed on its behalf by the undersigned
thereunto duly authorized.
Dated: October 15, 2008 ONCOLOGIX TECH, INC.
By: /s/ Judy Lindstrom
--------------------------------
Judy Lindstrom, President
By: /s/ Michael A. Kramarz
--------------------------------
Michael A. Kramarz,
Chief Financial Officer